EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Group I metabotropic glutamate receptors (mGluR1/5) and neurodegenerative diseases

E.I. Solntseva, P.D. Rogozin, V.G. Skrebitsky

Annals of Clinical and Experimental Neurology · 28.12.2019 · 13 (4)

DOI: 10.25692/acen.2019.4.8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Experimental Neurology, erschienen am 28.12.2019. Verfasst von E.I. Solntseva und 2 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This overview describes how group mGluR1/5 metabotropic glutamate receptors are involved in neurodegenerative diseases it also touches upon their use as therapeutic targets in animal models. mGluR1/5 are primarily located on the neuronal postsynaptic membrane, where they communicate with two proteins, Gq/11 and Homer, which, in turn, initiate several biochemical cascades. The Gq/11 protein cascade includes Са2 release from the endoplasmic reticulum (ER) through the inositol trisphosphate receptors (IP3R) and the activation of depot-controlled Са2 entry. The Gq/11 protein cascade also includes the production of diacylglycerol with subsequent activation of various protein kinases, which, in turn, provide influences on the genome. The Homer protein communicates directly with the NMDA receptors and Shank scaffold proteins, through which it regulates the activity of various protein kinases, including Akt and ERK1/2. The activation of mGluR1/5 triggers long-term depression of glutamatergic transmission through the endocytosis of AMPA receptors, caused by changes in the level of protein phosphorylation and genome activation. It is thought that mGluR1/5 play an important role in the development of neurodegenerative diseases. In Alzheimers disease, mGluR1/5 acts as a target for the -amyloid peptide. mGluR1/5 antagonists have a neuroprotective effect in transgenic mice with Alzheimers disease. The pathogenesis of Alzheimers disease includes increased Са2 release from the ER due to the pathological activity of mGluR1/5, as well as the influence of mutated presenilin on Са2 homeostasis in the ER. At the same time, restoration of Са2 levels in the ER is disrupted by the effect of presenilin on depot-activated Са2 entry. mGluR5 (but not mGluR1) is being studied as a potential therapeutic target in Parkinsons disease. Numerous studies on rodent and primate models of Parkinsons disease have demonstrated a significant antiparkinsonian effect when mGluR5 antagonists were used. It is thought that the neuroprotective mechanisms of action of mGluR5 antagonists involve limiting the increase in intracellular Са2 by reducing IP3 and NMDA receptor activation. Huntingtons disease is related to a mutation in the HTT gene and the ability of the mutant huntingtin protein to sensitise IP3 and NMDA receptors, thus triggering Са2 overload in the neurons. A neuroprotective effect in transgenic mice with Huntingtons disease was achieved by using positive allosteric modulators of mGluR5, capable of selectively activating cascades associated with the Homer protein and triggering Akt activation.

Zitieren

APA

Solntseva, E., Rogozin, P., & Skrebitsky, V. (2019). Group I metabotropic glutamate receptors (mGluR1/5) and neurodegenerative diseases. Annals of Clinical and Experimental Neurology, 13(4). https://doi.org/10.25692/acen.2019.4.8

Vancouver

Solntseva E, Rogozin P, Skrebitsky V. Group I metabotropic glutamate receptors (mGluR1/5) and neurodegenerative diseases. Annals of Clinical and Experimental Neurology. 2019;13(4). doi:10.25692/acen.2019.4.8

BibTeX
@article{Solntseva2019,
  author = {Solntseva, E.I. and Rogozin, P.D. and Skrebitsky, V.G.},
  title = {Group I metabotropic glutamate receptors (mGluR1/5) and neurodegenerative diseases},
  journal = {Annals of Clinical and Experimental Neurology},
  year = {2019},
  volume = {13},
  number = {4},
  doi = {10.25692/acen.2019.4.8}
}
Kostenlos starten →